{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:00:30Z","timestamp":1780902030589,"version":"3.54.1"},"reference-count":49,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>With the declining success rate of new drug development, lifecycle management strategies have become increasingly important. However, approximately 25\u201340% of approved drugs remain limited to a single indication. In this study, we compared drugs that obtained multiple indications with those confined to a single indication, aiming to identify factors associated with the acquisition of multiple indications. We identified anticancer drugs initially approved by US Food and Drug administration (FDA) between 2015 and 2020. This retrospective observational study includes 48 anticancer drugs for solid tumors. For each drug, data were collected on approved indications, sponsoring company characteristics, and clinical efficacy outcomes, including objective response rate (ORR) and progression-free survival (PFS). The drugs were categorized based on the number of approved indications, and comparative analyses were conducted. No clear association was observed between multiple indication acquisition and factors such as mechanism of action (MoA) or company size at the initial approval. Since additional indications may be obtained through various approaches\u2014including expansion to new tumor types or different lines of therapy\u2014no consistent relationship was observed between specific strategies and the acquisition of multiple indications. In contrast, drugs demonstrating higher clinical efficacy and those initially approved for non-rare cancers were more likely to achieve multiple indications. The factors associated with additional indications varied depending on the approach, and only a limited set of factors consistently correlated with multiple indication acquisition. Notably, clinical efficacy and the tumor type at initial approval appeared to be associated with acquisition of multiple indications. These findings provide important insights into research and development strategies and may inform decision-making in pharmaceutical lifecycle management.<\/jats:p>","DOI":"10.3390\/curroncol33060339","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identifying Factors Associated with the Acquisition of Multiple Indications for Anticancer Drugs"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7496-624X","authenticated-orcid":false,"given":"Shutaro","family":"Takahashi","sequence":"first","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi, Tokyo 204-8588, Japan"},{"name":"Portfolio and Project Management, Oncology Development, Astellas Pharma Inc., 2-5-1 Nihonbashi-Honcho Chuo-ku, Tokyo 103-8411, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0117-3961","authenticated-orcid":false,"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi, Tokyo 204-8588, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cts.12980","article-title":"Approval success rates of drug candidates based on target, action, modality, application, and their combinations","volume":"14","author":"Yamaguchi","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104291","DOI":"10.1016\/j.drudis.2025.104291","article-title":"Benchmarking R&D success rates of leading pharmaceutical companies: An empirical analysis of FDA approvals (2006\u20132022)","volume":"30","author":"Schuhmacher","year":"2025","journal-title":"Drug Discov. Today"},{"key":"ref_3","unstructured":"IQVIA (2025, November 04). Global Trends in R&D 2025: Progress in Recapturing Momentum in Biopharma Innovation. Available online: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-trends-in-r-and-d-2025."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103726","DOI":"10.1016\/j.drudis.2023.103726","article-title":"Analysis of pharma R&D productivity\u2014A new perspective needed","volume":"28","author":"Schuhmacher","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s43441-024-00706-6","article-title":"Subsequent Indications in Oncology Drugs: Pathways, Timelines, and the Inflation Reduction Act","volume":"59","author":"Patterson","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"103390","DOI":"10.1016\/j.drudis.2022.103390","article-title":"What is the importance of difference in LCM strategy in drug development?\u2014Learnings from Keytruda and Opdivo","volume":"27","author":"Kodama","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.drudis.2018.10.008","article-title":"Can lifecycle management safeguard innovation in the pharmaceutical industry?","volume":"23","author":"Hering","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_8","unstructured":"IQVIA (2025, November 04). Global Oncology Trends 2018: Innovation, Expansion and Disruption. Available online: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2018."},{"key":"ref_9","unstructured":"IQVIA (2025, December 20). Revealing Oncology\u2019s Hidden Dynamics. A New Dimension: MIDAS Disease Insights Series #1. Available online: https:\/\/www.iqvia.com\/locations\/emea\/blogs\/2024\/10\/revealing-oncologys-hidden-dynamics-a-new-dimension-midas-disease-insights-series-1."},{"key":"ref_10","unstructured":"Gores, M., and Scott, K. (2025, December 04). Success Multiplied: Launch Excellence for Multi-Indication Assets. IQVIA. Available online: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/iqvia-launch-excellence-for-multi-indication-assets-02-23-forweb.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10637-022-01227-5","article-title":"Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA","volume":"40","author":"Michaeli","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jval.2012.09.004","article-title":"What Is Wrong with Orphan Drug Policies?","volume":"15","author":"Keating","year":"2012","journal-title":"Value Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00228-016-2104-3","article-title":"Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006\u20132015: A cohort study","volume":"72","author":"Altman","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s43441-021-00364-y","article-title":"Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors","volume":"56","author":"Michaeli","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ha, S.-Y., Kang, D.-W., Jung, H.-I., Lee, E.-K., and Park, M.-H. (2022). Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19074105"},{"key":"ref_16","first-page":"47","article-title":"Price Models for Multi-indication Drugs: A Systematic Review","volume":"18","year":"2019","journal-title":"Appl. Health Econ. Health Policy"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Maes, I., Kok, E., De Torck, P.-J., Mestre-Ferrandiz, J., and Simoens, S. (2023). Not one, but many: Developing a multi-indication pricing model for medicines in Belgium. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1199253"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mills, M., Michaeli, D., Miracolo, A., and Kanavos, P. (2023). Launch sequencing of pharmaceuticals with multiple therapeutic indications: Evidence from seven countries. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09095-2"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s41669-024-00555-x","article-title":"Pricing for Multi-Indication Drugs in the Italian Regulatory Context","volume":"9","author":"Ursino","year":"2025","journal-title":"PharmacoEconomics\u2014Open"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Heine, R.J.S.D., Thielen, F.W., Mathijssen, R.H.J., van Leeuwen, R.W.F., Franken, M.G., and Groot, C.A.U.-D. (2024). Applying a cost-based pricing model for innovative cancer treatments subject to indication expansion: A case study for pembrolizumab and daratumumab. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0293264"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jval.2021.11.1376","article-title":"The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review","volume":"25","author":"Preckler","year":"2022","journal-title":"Value Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","article-title":"Special FDA designations for drug development: Orphan, fast track, accelerated approval, priority review, and breakthrough therapy","volume":"25","author":"Michaeli","year":"2024","journal-title":"Eur. J. Health Econ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s43441-022-00480-3","article-title":"Regulatory Pathways Supporting Expedited Drug Development and Approval in ICH Member Countries","volume":"57","author":"Franco","year":"2022","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_24","unstructured":"US Food and Drug Administration (2025, August 20). Drugs@FDA: FDA-Approved Drug Products. U S Food and Drug Administration [Website], Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm."},{"key":"ref_25","unstructured":"NIH (2025, August 20). Clinical Trials.gov, Available online: https:\/\/clinicaltrials.gov\/."},{"key":"ref_26","unstructured":"National Cancer Institute (2025, August 20). Cancer-Drug Dictionary. National Cancer Institute Website, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug."},{"key":"ref_27","unstructured":"IQVIA (2025, November 23). Emerging BioPharma\u2019s Contribution to Innovation; IQVIA Institute Report. Available online: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/emerging-biopharmas-contribution-to-innovation."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"Altman","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"ref_29","unstructured":"National Cancer Institute (2025, August 20). Rare Cancer Classification. National Cancer Institute Website, Available online: https:\/\/seer.cancer.gov\/seerstat\/variables\/seer\/raresiterecode\/."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1158\/1078-0432.CCR-23-3738","article-title":"FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Maguire","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-021-01319-8","article-title":"Determining lines of therapy in patients with solid cancers: A proposed new systematic and comprehensive framework","volume":"125","author":"Saini","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1358\/dot.2020.56.9.3170808","article-title":"Avapritinib for metastatic or unresectable gastrointestinal stromal tumors","volume":"56","author":"Alzofon","year":"2020","journal-title":"Drugs Today"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","article-title":"Tazemetostat: First Approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","article-title":"Pexidartinib (TURALIO\u2122): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor","volume":"20","author":"Monestime","year":"2020","journal-title":"Drugs RD"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1158\/1078-0432.CCR-15-1377","article-title":"FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine\u2013Refractory Differentiated Thyroid Cancer","volume":"21","author":"Nair","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions","volume":"27","author":"Bradford","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1097\/JS9.0000000000001044","article-title":"Celebrating a breakthrough: FDA endorses encorafenib plus binimetinib alongside two companion diagnostics for BRAV600E mutant metastatic non-small cell lung cancer","volume":"110","author":"Abbasi","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/jnci\/djad212","article-title":"Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations","volume":"116","author":"Michaeli","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1248\/bpb.b23-00149","article-title":"Comparison of Addition of Indications for Antineoplastic Agents Approved in the United States and Japan from 2001 to 2020","volume":"46","author":"Shizuya","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"ref_41","first-page":"433","article-title":"The evolving landscape of tissue-agnostic therapies in precision oncology","volume":"74","author":"Subbiah","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., and Wang, S. (2022). The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.964442"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12672-023-00758-4","article-title":"A target map of clinical combination therapies in oncology: An analysis of clinicaltrials.gov","volume":"14","author":"Yang","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13073-016-0369-x","article-title":"Approaches to modernize the combination drug development paradigm","volume":"8","author":"Day","year":"2016","journal-title":"Genome Med."},{"key":"ref_46","first-page":"E170","article-title":"Defining principles of combination drug mechanisms of action","volume":"110","author":"Pritchard","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cpt.194","article-title":"A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds","volume":"98","author":"DiMasi","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s43441-023-00509-1","article-title":"Factors Affecting Success of New Drug Clinical Trials","volume":"57","author":"Kim","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s43441-024-00718-2","article-title":"Pharmaceutical Company\u2019s Choices of Indication for the First Clinical Projects in Oncological Drug Development in the United States","volume":"59","author":"Wu","year":"2024","journal-title":"Ther. Innov. Regul. Sci."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T06:42:31Z","timestamp":1780900951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":49,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060339"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060339","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}